Another Sunday, another Pharma news update from Health and Life. What were the biggest news items of the last week and what might they mean?
Recent data indicates that aggressive control of diabetic patients markers related to disease like cholesterol levels may actually cause more harm than good.
We’ve already pointed out that science does not always dictate clinical guidelines, so we’re not surprised. Just disheartened.
The FDA has added a black box warning on Plavix. Up to 14% of those who use it may be genetically predisposed to a poor response.
Will this just confuse people? Could it be good news for Effient, a rising competitor?
AstraZeneca wins the first trial out of thousands alleging that its medication Seroquel caused diabetes. The case was brought by Ted Baker, 61.
Pfizer drops 8 year old patent infringement lawsuit against Eli Lilly over Viagra.
Sanofi agrees to settle class action lawsuit alleging that female sales reps were underpaid and pay $15.4 million.
Betrixaban, a Factor Xa inhibitor, has shown efficacy in a study of 508 patients for controlling major bleeding in atrial fibrillation and for some stroke patients.
Other factor X inhibitors like Apixaban seem to be much further along the pathway to development.
Chief of Abbot Laboratories Miles White had a 7% decrease in his package – but still made $26.2 million.
A recent high profile theft of pharmaceutical drugs from a Lilly distribution center has raised the question – how often does such theft happen? And how big a problem is it?
Some thoughts on what’s going on with Roche’s Avastin, a monoclonal antibody treatment for cancer that is controversial. On the one hand, it does have some benefit – on the other, Avastin is extremely expensive and the benefit is limited.
If you want to get the Weekly Pharma News Update and other important Pharmaceutical analysis, sign up for our PharmaWatch RSS feed.